PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders
Jamwal S, Blackburn J, Elsworth JD. PPARγ/PGC1α signaling as a potential therapeutic target for mitochondrial biogenesis in neurodegenerative disorders. Pharmacology & Therapeutics 2020, 219: 107705. PMID: 33039420, PMCID: PMC7887032, DOI: 10.1016/j.pharmthera.2020.107705.Peer-Reviewed Original ResearchConceptsNeurodegenerative disordersParkinson's diseaseAlzheimer's diseaseParaoxonase 2Mitochondrial biogenesisNeurodegenerative diseasesHuntington's diseasePeroxisome proliferator-activated receptorProliferator-activated receptorPotential therapeutic targetDevastating neurological disorderFunction of neuronsPeroxisome proliferator-activated receptor gamma co-activator-1 alphaPharmacological-based therapiesSymptomatic treatmentCurrent therapiesClinical trialsLigand-inducible transcription factorsTherapeutic targetNeurological disordersDiseasePPARγ modulatorsProgressive lossMitochondrial dysfunctionPromising targetPioglitazone activates paraoxonase-2 in the brain: A novel neuroprotective mechanism
Blackburn JK, Curry DW, Thomsen AN, Roth RH, Elsworth JD. Pioglitazone activates paraoxonase-2 in the brain: A novel neuroprotective mechanism. Experimental Neurology 2020, 327: 113234. PMID: 32044330, PMCID: PMC7089823, DOI: 10.1016/j.expneurol.2020.113234.Peer-Reviewed Original ResearchConceptsParaoxonase 2Novel neuroprotective mechanismParaoxonase-2 expressionAnti-diabetic drug pioglitazoneReactive oxygen species productionNeuroprotective strategiesNeuroprotective mechanismsBrain traumaMouse striatumOxygen species productionParkinson's diseaseAlzheimer's diseaseTherapeutic potentialPioglitazoneDiseaseOxidative stressDrug pioglitazoneSpecies productionBrainNeuroprotectionIschemiaStriatumExpressionPathologyTrauma